Conclusions
The recommended phase 2 doses and schedules for this combination are
topotecan 0.75mg/m2 IV days 1-5, cyclophosphamide
250mg/m2 IV days 1-5, and cabozantinib
25mg/m2 days 8-21. Non-concomitant administration of
cabozantinib with cytotoxic therapy in this population has acceptable
toxicity while allowing for potential disease control.